Recombinant activated factor VII (rFVIIa) is a powerful prohaemostatic agent that theoretically predisposes to thrombosis after peripheral vascular surgery. We report the use of rFVIIa to reduce bleeding in a patient after axillofemoral bypass grafting for ruptured aorto-iliac pseudoaneurysm. Despite the increased risk of thrombosis, the patient made an uneventful recovery with preserved graft patency. The favourable result suggests that rFVIIa should be considered even in vascular surgical patients, if the risks of continued bleeding outweigh those of thrombosis. Better risk estimation is only possible if reports of rFVIIa use in vascular patients continue to appear and through controlled trials.
Recombinant activated factor VII (rFVIIa, novoSeven®, novo nordisk AS, Denmark) is approved for treatment of bleeding in haemophilia patients with inhibitors 1 . It has also been increasingly used for improving coagulation in the presence of a variety of haemostatic disorders, including during the perioperative period 1 .
RFVIIa combines with tissue factor (TF) in the subendothelium of damaged blood vessels to create a thrombin burst 1 . Pharmacologic doses of rFVIIa also activate Factor X (FX) directly on the surface of activated platelets at the site of injury, independent of TF, to increase thrombin generation in the absence of FVIII or FIX 1 . As such, rFVIIa greatly augments clot formation only where it is needed at damaged blood vessel sites. Therein lies the concern with the use of this potent agent in vascular surgical patients, in whom TF may be expressed, and activated platelets may aggregate at vessel grafts. In addition, TF is present in vascular plaques 2 and circulates at increased levels in patients with atherosclerosis 3 . The decision to use rFVIIa in a vascular surgical patient who has uncontrolled bleeding must therefore be made by balancing the risks of haemorrhage and blood transfusion, and the theoretical risk of thromboembolism. however, current evidence suggests that the thrombosis risk is low although potential serious adverse events remain a concern 4,5 .
CASe hISToRY
A 64-year-old man presented with right leg pain, fever and chills. Two years prior to this, he had an infected right common iliac artery aneurysm managed with polytetrafluoroethylene (PTFe) inlay grafting and antibiotics. other medical history included diabetes mellitus and hypertension. on examination, his temperature was 40°C, heart rate was 90/min, blood pressure was 140/63 mmhg, and there was right leg weakness. Laboratory results were: haemoglobin 12.8 g/dl, white cell count 12.1 × 10 9 /l (93% neutrophils), InR 3.43, APTT 120s (normal range 25.2-38.2), urea 14 mmol/l (normal range 3.4-8.9), creatinine 249 µmol/l (normal range 62-106), bilirubin 76 µmol/l (normal <15), creatine kinase 24,300 U/l (normal range 42-218), with myoglobinuria present. Initial platelet count was unavailable due to clumping. Ultrasound demonstrated a 7×6×12 cm multiloculated cystic lesion in the right psoas muscle suggestive of an abscess. A CT scan of the abdomen showed extravasation around the right iliac graft anastomosis into the right psoas muscle. There was right hydronephrosis and hydroureter due to compression from the expanded psoas muscle and haematoma.
Antibiotics were commenced and the patient underwent surgery after receiving fresh frozen plasma (FFP) and platelets. Intraoperative findings confirmed a pseudoaneurysm at the aorto to right common iliac PTFe graft junction with haematoma around the right psoas muscle. The graft was removed and the right common iliac stump ligated. An axillofemoral vascular bypass was performed using a PTFe graft. Surgery was complicated by massive bleeding, haemodynamic instability (requiring vasopressors), oliguria, metabolic acidosis, and coagulopathy. Blood loss of 3 litres was recorded, with the patient receiving 4 litres of crystalloid (normal saline), 1 litre of colloid (succinylated gelatin, Gelofusine, BBraun), blood 7 units (leucocyte-reduced homologous packed red cells), FFP 4 units and platelets 12 units. Postoperatively, he continued to bleed with increasing abdominal distension, increasing vasopressor requirements, metabolic acidosis and falling haemoglobin. Tympanic membrane temperature when the patient first arrived from the operating theatre was 34.5°C and active rewarming was instituted. A second laparotomy was performed two hours later, at which a haemoperitoneum of 600 ml was found with generalized oozing but no identifiable bleeding points. The abdomen was packed with gauzes and the abdominal wound closed. Following a second laparotomy, the intra-abdominal pressure as measured by bladder manometry was 29 cm h 2 o and there was further deterioration in renal function. More blood, FFP and platelets were given, and despite normothermia (temperature warmed from 32.1°C to 36.8°C after the second laparotomy), bleeding continued. other complications included rapid atrial fibrillation, anuria, elevated central venous pressures, high ventilatory requirements and pulmonary congestion. Poor vascular access precluded renal replacement therapy. The coagulation parameters are shown in Figure 1 .
After weighing the potential risk of thrombosis with the consequences of continued bleeding, we gave rFVIIa at the dose of 100 µg/kg intravenously. The patient's condition quickly stabilized; no further transfusions were required, coagulation parameters improved, vasopressors were reduced and the abdomi- nal pressure gradually decreased to 22 cm h 2 o. The patient had a third laparotomy 24 hours later, during which no further bleeding was found. The patient made a gradual recovery and was discharged to the ward five days later. When discharged one month later, his lower limb perfusion was good and he was able to walk independently. A Burkholderia species was isolated from the blood culture and pseudoaneurysm wall.
DISCUSSIon
RFVIIa has been used effectively to stop refractory 'medical' bleeding in numerous settings 1 , but apparently has never been reported after peripheral vascular surgery. We have successfully used this agent in a patient who had undergone axillofemoral bypass grafting. Graft thrombosis is a recognized and feared complication of peripheral vascular procedures. Additionally, long extraanatomic reconstructions, e.g. axillofemoral grafts have inherently a lower patency rate than aortofemoral bypass grafts. Factors that cause graft failure in this type of bypass include the use of a prosthetic material, with increased thrombogenicity and infection, and inadequate outflow. Although this case does not prove that rFVIIa use is safe in all peripheral vascular patients with prosthetic grafts, it suggests that rFVIIa should not be automatically eliminated as an option in such patients. It is known that TF:FVIIa complexes on damaged vessel walls become rapidly blanketed by platelets 2 , and it is possible that by the time our patient was administered rFVIIa, no more exposed TF were available on the repaired vessels. In our opinion, the uncomplicated use of rFVIIa in cardiac 6, 9, 10 and aortic surgical 7, [11] [12] [13] patients also lends support to keeping rFVIIa as an option in vascular patients with uncontrolled "medical" bleeding. of particular interest is that rFVIIa had been used successfully in two cases of coronary artery bypass grafting in eikelboom and co-workers' series 8 . Graft thrombosis in these patients apparently did not occur.
We used rFVIIa only after exhausting all conventional therapy. Antifibrinolytics were not given as disseminated intravascular coagulation from sepsis was suspected for which this group of drugs are generally contraindicated 14, 15 . Given that bleeding continued and serious complications were developing rapidly, the risk of not using rFVIIa appeared to be far greater than using it. Although there has been a wide variation of doses used in the published data so far, the recommended initial dose of rFVIIa for massive bleeding has been between 90 and 120 µg/kg 16, 17, 18 . It has also been recommended that if haemorrhage persists shortly after the first dose, an additional but smaller dose should be considered 18 . We chose the dose of 100 µg/kg for easy calculation, rounded off to the nearest 1.2 mg.
The risk of rFVIIa-associated thromboembolic complications is a matter of great interest. Between 1996 and April 2003 there had been over 700,000 doses of factor VIIa (90 µg/kg) administered to several thousand patients with congenital or acquired haemophilia. Sixteen thrombotic events (ten acute myocardial infarction or cerebrovascular accidents and six venous thrombosis), and two cases of disseminated intravascular coagulation were reported in the literature 4 . Most of the affected patients were elderly, had atherosclerosis, known coronary artery disease, diabetes, obesity, severe infection and other prothrombotic conditions 5 . These data suggest that even if all the thrombotic events had been caused mainly by rFVIIa, the risk is low. however, thrombotic events whose link to rFVIIa 19-23 cannot be confidently excluded continue to be reported sporadically, reminding us that the risk is probably not zero. Better estimates of this risk in vascular patients will, with time, emerge as clinicians continue to report its use both in open-label use and in controlled trials together. Useful information on estimates of risks may also be obtained from usage registers such as the haemostasis Registry which has been established by Monash University.
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